Clinical Trials · NCT05974774
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Enrollment
- 1,600
- Start date
- May 2025
- Locations
- 9 sites, 3 countries
- Primary endpoint
- overall survival